
WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I),


or a pharmaceutically acceptable salt thereof, wherein

R^1 is

i) C_{6-10} aryl or 6-membered heteroaryl, each of which is optionally substituted with one to four R^4; or

ii) 6-membered heteroaryl, wherein the heteroaryl is fused to a 5- or 6-membered ring having zero to three heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to four R^5;

ring A is



, which are each optionally substituted with one to three R^A, each R^A independently C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, -OH, -CN, or -N(R^{10a})(R^{10b});

ring B is

(i) C_{6-10} aryl or heteroaryl, which is each optionally substituted with one to four R^B, each R^B independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -NO_2, -CN, -N_3, -O-R^{10a}, -C(O)R^{10a}, -C(O)O- R^{10a}, -N(R^{10a})(R^{10b}), N(R^{10a})$_2$(R^{10b})$^+$, -N(R^{10a})C(O)- R^{10b}, -N(R^{10a})C(O)O- R^{10b}, -N(R^{10a})C(O)N(R^{10b})(R^{10c}), -N(R^{10a})S(O)$_2$(R^{10b}), -N R^{10a}S(O)$_2$N(R^{10b})(R^{10c}), -N R^{10a}S(O)$_2$O(R^{10b}), -OC(O) R^{10a}, -OC(O)O R^{10a}, -OC(O)-N(R^{10a})(R^{10b}), -S-R^{10a}, -S(O) R^{10a}, -S(O)(NH) R^{10a}, -S(O)$_2$ R^{10a}, -S(O)$_2$N(R^{10a})(R^{10b}), -S(O)(N R^{10a}) R^{10b}, or -Si(R^{10a})$_3$; or

(ii) C_{6-10} aryl or heteroaryl, which is each fused to a 5 or 6 membered ring having zero to four heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to five R^B, each R^B independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6}

alkenyl, C_{2-6} alkynyl, halogen, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, $-NO_2$, -CN, $-N_3$, $-O-R^{10a}$, $-C(O)R^{10a}$, $-C(O)O-R^{10a}$, $-N(R^{10a})(R^{10b})$, $N(R^{10a})_2(R^{10b})^+$, $-N(R^{10a})C(O)-R^{10b}$, $-N(R^{10a})C(O)O-R^{10b}$, $-N(R^{10a})C(O)N(R^{10b})(R^{10c})$, $-N(R^{10a})S(O)_2(R^{10b})$, $-N R^{10a}S(O)_2N(R^{10b})(R^{10c})$, $-N R^{10a}S(O)_2O(R^{10b})$, $-OC(O) R^{10a}$, $-OC(O)O R^{10a}$, $-OC(O)-N(R^{10a})(R^{10b})$, $-S-R^{10a}$, $-S(O) R^{10a}$, $-S(O)(NH) R^{10a}$, $-S(O)_2 R^{10a}$, $-S(O)_2N(R^{10a})(R^{10b})$, $-S(O)(N R^{10a}) R^{10b}$, or $-Si(R^{10a})_3$;


V is $-C(R^{11a})(R^{11b})-$;

X^1, X^2, and X^3 are each independently -C(H)=, or $-C(R^8)=$;

R^2 is

i) C_{3-10} cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted with one to four Z^1, wherein each Z^1 is independently C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, oxo, -OH, -CN, C_{1-6} alkyl-CN, $-C(O)R^{10a}$, $-C(O)O-R^{10a}$, $-C(O)NH_2$, $-C(O)NH(C_{1-9}$ alkyl), $-N(R^{10a})(R^{10b})$, $-N(R^{10a})C(O)O-R^{10b}$, $-N(R^{10a})C(O)-R^{10b}$, $-S(O)_2R^{10a}$, $-S(O)_2(C_{1-9}$ alkyl), $-O-C_{3-6}$ cycloalkyl or heteroaryl,

wherein each $-O-C_{3-6}$ cycloalkyl or heteroaryl is optionally substituted with one to four Z^{1a} groups, each Z^{1a} independently C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy; or

ii) 

, wherein

R^{2a} is C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-CN, $-C_{3-6}$ cycloalkyl or heteroaryl,

wherein each alkyl, cycloalkyl, or heteroaryl is optionally substituted with one to four groups each independently C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy;

R^{2b} is H, C_{1-3} alkyl, C_{1-3} haloalkyl; and

R^{2c} is H, C_{1-3} alkyl, C_{1-3} haloalkyl;

R^3 is $-C(O)OR^{3a}$,

wherein R^{3a} is H, C_{1-4} alkyl-$N(R^{9a})(R^{9b})$, $-C_{1-4}$ alkyl-$N(R^{9a})C(O)-O-C_{1-4}$ alkyl-$OP(O)(OR^{9c})_2$, C_{1-4} alkyl-$C(O)N(R^{9a})(R^{9b})$, $-C_{1-4}$ alkyl-$O-C(O)-C_{1-4}$ alkyl, $-C_{1-4}$

alkyl-O-C(O)-O-C_{1-4}alkyl, -C_{1-4} alkyl-O-C(O)-C_{1-4} alkyl-N(R^{9a})(R^{9b}), -C_{1-4} alkyl-O-C(O)-C_{1-4} alkyl-OP(O)(OR^{9c})$_2$, -$CH_2CH(N(R^{9a})_2)C(O)OR^{9b}$, -P(O)($OR^{9c}$)$_2$, -OP(O)($OR^{9c}$)$_2$, -$CH_2P(O)(OR^{9c})_2$, -$CH_2OP(O)(OR^{9c})_2$, -$OCH_2P(O)(OR^{9c})_2$, C(O)$OCH_2P(O)(OR^{9c})_2$, -P(O)($R^{9c}$)($OR^{9d}$), -OP(O)($R^{9c}$)($OR^{9d}$), -$CH_2P(O)(R^{9c})(OR^{9d})$, -$OCH_2P(O)(R^{9c})(OR^{9d})$, -C(O)$OCH_2P(O)(R^{9c})(OR^{9d})$, -P(O)($N(R^{9c})_2$)$_2$, -OP(O)($N(R^{9c})_2$)$_2$, -$CH_2P(O)(N(R^{9c})_2)_2$, -$OCH_2P(O)(N(R^{9c})_2)_2$, -C(O)$OCH_2P(O)(N(R^{9c})_2)_2$, -P(O)($N(R^{9c})_2$)($OR^{9d}$), -OP(O)($N(R^{9c})_2$)($OR^{9d}$), -$CH_2P(O)(N(R^{9c})_2)(OR^{9d})$, -$OCH_2P(O)(N(R^{9c})_2)(OR^{9d})$, -C(O)$OCH_2P(O)(N(R^{9c})_2)(OR^{9d})$, -P(O)($R^{9c}$)($N(R^{9d})_2$), -OP(O)($R^{9c}$)($N(R^{9d})_2$), -$CH_2P(O)(R^{9c})(N(R^{9d})_2)$, -$OCH_2P(O)(R^{9c})(N(R^{9d})_2)$, -C(O)$OCH_2P(O)(R^{9c})(N(R^{9d})_2)$, or C_{1-6} alkyl-heterocyclyl,

wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;

each R^4 is independently C_{1-6} alkyl, C_{1-8} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, halogen, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -NO_2, -CN, -N_3, -O-R^{10a}, -C(O)R^{10a}, -C(O)O-R^{10a}, -N(R^{10a})(R^{10b}), -$N(R^{10a})_2(R^{10b})^+$, -N(R^{10a})-C(O)R^{10b}, -N(R^{10a})C(O)O(R^{10b}), -N(R^{10a})C(O)N(R^{10b})(R^{10c}), -N(R^{10a})S(O)$_2$(R^{10b}), -N(R^{10a})S(O)$_2$-N(R^{10b})(R^{10c}), -N(R^{10a})S(O)$_2$O(R^{10b}), -OC(O)R^{10a}, -OC(O)OR^{10a}, -OC(O)-N(R^{10a})(R10^b), -S-R10^a, -S(O)R^{10a}, -S(O)(NH)R^{10a}, -$S(O)_2R^{10a}$, -$S(O)_2N(R^{10a})(R^{10b})$, -S(O)($NR^{10a}$)$R^{10b}$, or -$Si(R^{10a})_3$,

wherein each alkyl, haloalkyl, alkenyl or aryl is optionally substituted with one to four R^5, and

wherein each cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one to four R^{12};

each $R^5$is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -NO_2, -N_3, -CN, -O-R^{10a}, -C(O)-R^{10a}, -C(O)O-R^{10a}, C(O)-N(R^{10a})(R^{10b}), -N(R^{10a})(R^{10b}), -$N(R^{10a})_2(R^{10b})^+$, -N(R R^{10a})C(O)- R^{10b}, -N(R^{10a})C(O)O-R^{10b}, -N(R^{10a})C(O)N(R^{10b})(R^{10c}), -N(R^{10a})S(O)$_2$(R^{10b}), -N R^{10a}S(O)$_2$N(R^{10b})(R^{10c}), -N R^{10a}S(O)$_2$O(R^{10b}), -OC(O) R^{10a}, -OC(O)O R^{10a}, -OC(O)-N(R^{10a})(R^{10b}), -S-R^{10a}, -S(O) R^{10a}, -S(O)(NH) R^{10a}, -$S(O)_2$ R^{10a}, -$S(O)_2N(R^{10a})$(R^{10b}), -S(O)(N R^{10a}) R^{10b}, or -$Si(R^{10a})_3$,

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to four R^6;

each R^6 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, $-NO_2$, $-N_3$, -CN, -O- R^{10a}, -C(O)- R^{10a}, -C(O)O- R^{10a}, -C(O)-N(R^{10a})(R^{10b}), -N(R^{10a})(R^{10b}), -N(R^{10a})C(O)- R^{10b}, -N(R^{10a})C(O)O- R^{10b}, -N(R^{10a})C(O)N(R^{10b})(R^{10c}), -N(R^{10a})S(O)$_2$(R^{10b}), -N R^{10a}S(O)$_2$N(R^{10b})(R^{10c}), -N R^{10a}S(O)$_2$O(R^{10b}), -OC(O) R^{10a}, -OC(O)O R^{10a}, -OC(O)-N(R^{10a})(R^{10b}), -S-R^{10a}, -S(O) R^{10a}, -S(O)(NH) R^{10a}, -S(O)$_2$ R^{10a}, -S(O)$_2$N(R^{10a})(R^{10b}), -S(O)(N R^{10a}) R^{10b}, or -Si(R^{10a})$_3$,

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to four R^7;

each R^7 and R^8 is independently C_{1-9} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -OH, -CN, $-NO_2$, $-NH_2$, $-N_3$, -SH, -O(C_{1-9} alkyl), -O(C_{1-8} haloalkyl), -O(C_{2-6} alkenyl), -O(C_{2-6} alkynyl), -O(C_{3-15} cycloalkyl), -O(heterocyclyl), -O(C_{6-10} aryl), -O(heteroaryl), -NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{2-6} alkenyl), -NH(C_{2-6} alkynyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(C_{6-10} aryl), -NH(heteroaryl), -N(C_{1-9} alkyl)$_2$, -N(C_{1-8} haloalkyl)$_2$, -N(C_{2-6} alkenyl)$_2$, -N(C_{2-6} alkynyl)$_2$, -N(C_{3-15} cycloalkyl)$_2$, -N(heterocyclyl)$_2$, -N(C_{6-10} aryl)$_2$, -N(heteroaryl)$_2$, -N(C_{1-9} alkyl)(C_{1-8} haloalkyl), -N(C_{1-9} alkyl)(C_{2-6} alkenyl), -N(C_{1-9} alkyl)(C_{2-6} alkynyl), -N(C_{1-9} alkyl)(C_{3-15} cycloalkyl), -N(C_{1-9} alkyl)(heterocyclyl), -N(C_{1-9} alkyl)(C_{6-10} aryl), -N(C_{1-9} alkyl)(heteroaryl), -C(O)(C_{1-9} alkyl), -C(O)(C_{1-8} haloalkyl), -C(O)(C_{2-6} alkenyl), -C(O)(C_{2-6} alkynyl), -C(O)(C_{3-15} cycloalkyl), -C(O)(heterocyclyl), -C(O)(C_{6-10} aryl), -C(O)(heteroaryl), -C(O)O(C_{1-9} alkyl), -C(O)O(C_{1-8} haloalkyl), -C(O)O(C_{2-6} alkenyl), -C(O)O(C_{2-6} alkynyl), -C(O)O(C_{3-15} cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C_{6-10} aryl), -C(O)O(heteroaryl), -C(O)NH_2, -C(O)NH(C_{1-9} alkyl), -C(O)NH(C_{1-8} haloalkyl), -C(O)NH(C_{2-6} alkenyl), -C(O)NH(C_{2-6} alkynyl), -C(O)NH(C_{3-15} cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C_{6-10} aryl), -C(O)NH(heteroaryl), -C(O)N(C_{1-9} alkyl)$_2$, -C(O)N(C_{1-8} haloalkyl)$_2$, -C(O)N(C_{2-6} alkenyl)$_2$, -C(O)N(C_{2-6} alkynyl)$_2$, -C(O)N(C_{3-15} cycloalkyl)$_2$, -C(O)N(heterocyclyl)$_2$, -C(O)N(C_{6-10} aryl)$_2$, -C(O)N(heteroaryl)$_2$, -NHC(O)(C_{1-9} alkyl), -NHC(O)(C_{1-8} haloalkyl), -NHC(O)(C_{2-6} alkenyl), -NHC(O)(C_{2-6} alkynyl), -NHC(O)(C_{3-15}

cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C_{6-10} aryl), -NHC(O)(heteroaryl), -NHC(O)O(C_{1-9} alkyl), -NHC(O)O(C_{1-8} haloalkyl), -NHC(O)O(C_{2-6} alkenyl), -NHC(O)O(C_{2-6} alkynyl), -NHC(O)O(C_{3-15} cycloalkyl), -NHC(O)O(heterocyclyl),-NHC(O)O(C_{6-10} aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C_{1-9} alkyl), -NHC(O)NH(C_{1-8} haloalkyl), -NHC(O)NH(C_{2-6} alkenyl), -NHC(O)NH(C_{2-6} alkynyl), -NHC(O)NH(C_{3-15} cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C_{6-10} aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C_{1-9} alkyl), -N(C_{1-9} alkyl)(S(O)(C_{1-9} alkyl), -S(C_{1-9} alkyl), -S(C_{1-8} haloalkyl), -S(C_{2-6} alkenyl), -S(C_{2-6} alkynyl), -S(C_{3-15} cycloalkyl), -S(heterocyclyl), -S(C_{6-10} aryl), -S(heteroaryl), -S(O)N(C_{1-9} alkyl)$_2$, -S(O)(C_{1-9} alkyl), -S(O)(C_{1-8} haloalkyl), -S(O)(C_{2-6} alkenyl), -S(O)(C_{2-6} alkynyl), -S(O)(C_{3-15} cycloalkyl), -S(O)(heterocyclyl), -S(O)(C_{6-10} aryl), -S(O)(heteroaryl), -S(O)$_2$(C_{1-9} alkyl), -S(O)$_2$(C_{1-8} haloalkyl), -S(O)$_2$(C_{2-6} alkenyl), -S(O)$_2$(C_{2-6} alkynyl), -S(O)$_2$(C_{3-15} cycloalkyl), -S(O)$_2$(heterocyclyl), -S(O)$_2$(C_{6-10} aryl), -S(O)$_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -S(O)$_2$NH(C_{1-9} alkyl), or -S(O)$_2$N(C_{1-9} alkyl)$_2$,

wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to three C_{1-9} alkyl, C_{1-8} haloalkyl, halogen, -OH, -NH_2, CO_2H,-O(C_{1-9} alkyl), -O(C_{1-8} haloalkyl), -O(C_{3-15} cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C_{1-9} alkyl)$_2$, -N(C_{3-15} cycloalkyl)$_2$, -NHC(O)(C_{1-8} haloalkyl), -NHC(O)(C_{3-15} cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C_{1-9} alkyl), -NHC(O)O(C_{1-8} haloalkyl), -NHC(O)O(C_{2-6} alkynyl), -NHC(O)O(C_{3-15} cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C_{1-9} alkyl), S(O)$_2$(C_{1-9} alkyl), -S(O)$_2$(C_{1-8} haloalkyl), -S(O)$_2$(C_{3-15} cycloalkyl), -S(O)$_2$(heterocyclyl), -S(O)$_2$(aryl), -S(O)$_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -S(O)$_2$NH(C_{1-9} alkyl), or -S(O)$_2$N(C_{1-9} alkyl)$_2$,

wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;

each R^{9a} and R^{9b} is independently H, C_{1-6} alkyl, or C_{1-6} haloalkyl, or R^{9a} and R^{9b} together form a 6-membered heterocyclyl;

each R^{9c}, R^{9d}, R^{10a}, R^{10b}, and R^{10c} is independently H, C_{1-9} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl, wherein the alkyl, alkenyl,

alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four R^6;

each R^{11a} and R^{11b} is independently -H, C_{1-6} alkyl, oxo, or halogen;

each R^{12} is C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, , oxo, -OH, -CN, $-NO_2$, $-NH_2$, $-N_3$, -SH, $-O(C_{1-9}$ alkyl), $-O(C_{1-8}$ haloalkyl), $-O(C_{2-6}$ alkenyl), $-O(C_{2-6}$ alkynyl), $-O(C_{3-15}$ cycloalkyl), -O(heterocyclyl), $-O(C_{6-10}$ aryl), -O(heteroaryl), $-NH(C_{1-9}$ alkyl), $-NH(C_{1-8}$ haloalkyl), $-NH(C_{2-6}$ alkenyl), $-NH(C_{2-6}$ alkynyl), $-NH(C_{3-15}$ cycloalkyl), -NH(heterocyclyl), $-NH(C_{6-10}$ aryl), -NH(heteroaryl), $-N(C_{1-9}$ alkyl)$_2$, $-N(C_{1-8}$ haloalkyl)$_2$, $-N(C_{2-6}$ alkenyl)$_2$, $-N(C_{2-6}$ alkynyl)$_2$, $-N(C_{3-15}$ cycloalkyl)$_2$, -N(heterocyclyl)$_2$, $-N(C_{6-10}$ aryl)$_2$, -N(heteroaryl)$_2$, $-N(C_{1-9}$ alkyl)(C_{1-8} haloalkyl), $-N(C_{1-9}$ alkyl)(C_{2-6} alkenyl), $-N(C_{1-9}$ alkyl)(C_{2-6} alkynyl), $-N(C_{1-9}$ alkyl)(C_{3-15} cycloalkyl), $-N(C_{1-9}$ alkyl)(heterocyclyl), $-N(C_{1-9}$ alkyl)(C_{6-10} aryl), $-N(C_{1-9}$ alkyl)(heteroaryl), $-C(O)(C_{1-9}$ alkyl), $-C(O)(C_{1-8}$ haloalkyl), $-C(O)(C_{2-6}$ alkenyl), $-C(O)(C_{2-6}$ alkynyl), $-C(O)(C_{3-15}$ cycloalkyl), -C(O)(heterocyclyl), $-C(O)(C_{6-10}$ aryl), -C(O)(heteroaryl), $-C(O)O(C_{1-9}$ alkyl), $-C(O)O(C_{1-8}$ haloalkyl), $-C(O)O(C_{2-6}$ alkenyl), $-C(O)O(C_{2-6}$ alkynyl), $-C(O)O(C_{3-15}$ cycloalkyl), -C(O)O(heterocyclyl), $-C(O)O(C_{6-10}$ aryl), -C(O)O(heteroaryl), $-C(O)NH_2$, $-C(O)NH(C_{1-9}$ alkyl), $-C(O)NH(C_{1-8}$ haloalkyl), $-C(O)NH(C_{2-6}$ alkenyl), $-C(O)NH(C_{2-6}$ alkynyl), $-C(O)NH(C_{3-15}$ cycloalkyl), -C(O)NH(heterocyclyl), $-C(O)NH(C_{6-10}$ aryl), -C(O)NH(heteroaryl), $-C(O)N(C_{1-9}$ alkyl)$_2$, $-C(O)N(C_{1-8}$ haloalkyl)$_2$, $-C(O)N(C_{2-6}$ alkenyl)$_2$, $-C(O)N(C_{2-6}$ alkynyl)$_2$, $-C(O)N(C_{3-15}$ cycloalkyl)$_2$, -C(O)N(heterocyclyl)$_2$, $-C(O)N(C_{6-10}$ aryl)$_2$, -C(O)N(heteroaryl)$_2$, $-NHC(O)(C_{1-9}$ alkyl), $-NHC(O)(C_{1-8}$ haloalkyl), $-NHC(O)(C_{2-6}$ alkenyl), $-NHC(O)(C_{2-6}$ alkynyl), $-NHC(O)(C_{3-15}$ cycloalkyl), -NHC(O)(heterocyclyl), $-NHC(O)(C_{6-10}$ aryl), -NHC(O)(heteroaryl), $-NHC(O)O(C_{1-9}$ alkyl), $-NHC(O)O(C_{1-8}$ haloalkyl), $-NHC(O)O(C_{2-6}$ alkenyl), $-NHC(O)O(C_{2-6}$ alkynyl), $-NHC(O)O(C_{3-15}$ cycloalkyl), -NHC(O)O(heterocyclyl),$-NHC(O)O(C_{6-10}$ aryl), -NHC(O)O(heteroaryl), $-NHC(O)NH(C_{1-9}$ alkyl), $-NHC(O)NH(C_{1-8}$ haloalkyl), $-NHC(O)NH(C_{2-6}$ alkenyl), $-NHC(O)NH(C_{2-6}$ alkynyl), $-NHC(O)NH(C_{3-15}$ cycloalkyl), -NHC(O)NH(heterocyclyl), $-NHC(O)NH(C_{6-10}$ aryl), -NHC(O)NH(heteroaryl), $-NHS(O)(C_{1-9}$ alkyl), $-N(C_{1-9}$ alkyl)$(S(O)(C_{1-9}$ alkyl), $-S(C_{1-9}$ alkyl), $-S(C_{1-8}$ haloalkyl), $-S(C_{2-6}$ alkenyl), $-S(C_{2-6}$ alkynyl), $-S(C_{3-15}$ cycloalkyl), -S(heterocyclyl), $-S(C_{6-10}$ aryl), -S(heteroaryl), $-S(O)N(C_{1-9}$ alkyl)$_2$, $-S(O)(C_{1-9}$ alkyl), $-S(O)(C_{1-8}$ haloalkyl), $-S(O)(C_{2-6}$ alkenyl), $-S(O)(C_{2-6}$ alkynyl), $-S(O)(C_{3-15}$ cycloalkyl),

-S(O)(heterocyclyl), -S(O)(C_{6-10} aryl), -S(O)(heteroaryl), -$S(O)_2$(C_{1-9} alkyl), -$S(O)_2$(C_{1-8} haloalkyl), -$S(O)_2$(C_{2-6} alkenyl), -$S(O)_2$(C_{2-6} alkynyl), -$S(O)_2$(C_{3-15} cycloalkyl), -$S(O)_2$(heterocyclyl), -$S(O)_2$(C_{6-10} aryl), -$S(O)_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -$S(O)_2$NH(C_{1-9} alkyl), or -$S(O)_2$N(C_{1-9} alkyl)$_2$,

wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to three C_{1-9} alkyl, C_{1-8} haloalkyl, halogen, -OH, -NH_2, CO_2H,-O(C_{1-9} alkyl), -O(C_{1-8} haloalkyl), -O(C_{3-15} cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C_{1-9} alkyl)$_2$, -N(C_{3-15} cycloalkyl)$_2$, -NHC(O)(C_{1-8} haloalkyl), -NHC(O)(C_{3-15} cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C_{1-9} alkyl), -NHC(O)O(C_{1-8} haloalkyl), -NHC(O)O(C_{2-6} alkynyl), -NHC(O)O(C_{3-15} cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C_{1-9} alkyl), S$(O)_2$(C_{1-9} alkyl), -$S(O)_2$(C_{1-8} haloalkyl), -$S(O)_2$(C_{3-15} cycloalkyl), -$S(O)_2$(heterocyclyl), -$S(O)_2$(aryl), -$S(O)_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -$S(O)_2$NH(C_{1-9} alkyl), or -$S(O)_2$N(C_{1-9} alkyl)$_2$,

wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;

wherein each heterocyclyl has three to twelve ring members and has one to four heteroatoms, each independently N, O, or S; and

wherein each heteroaryl has five to twelve ring members and one to four heteroatoms, each independently N, O, or S.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


R^1 is phenyl or 6-membered heteroaryl, each of which is optionally substituted with one to four R^4.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is 6-membered heteroaryl, wherein the heteroaryl is fused to a 5- or 6-membered ring having zero to three heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to four R^5.

4. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein




ring A is



, which is optionally substituted with one to three R^A.

5. The compound of any of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein

ring A is

, ,or , which are each optionally substituted with one to three R^A.




6. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each R^A is independently C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, halogen, -OH, or $-N(R^{10a})(R^{10b})$.

7. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

ring B is phenyl or 5 to 6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted with one to four R^B.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein

ring B is









, , or , which is optionally substituted with one to four R^B.

9. The compound of any of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein

ring B is phenyl or 5 to 6 membered heteroaryl, which is each fused to a 5 or 6 membered ring having zero to four heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to five R^B.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein ring B is

, , , or , which is optionally substituted with one to five R^B.

11. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof wherein, each R^B is independently C_{1-9} alkyl, C_{1-8} haloalkyl, halogen, heteroaryl, oxo, or $-N(R^{10a})(R^{10b})$.

12. The compound of any of the preceding claims, or pharmaceutically acceptable salt thereof, wherein

V is $-CH_2-$, $-C(O)-$, $-C(F)_2-$, $-CH(F)-$, or $-CH(CH_3)-$.

13. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein


X^1, X^2, and X^3 are each independently $-CH=$, $-C(Br)=$, $-C(C{\equiv}CCH_2CH_2CH_3)=$, or $-C(C{\equiv}CC(CH_3)(CH_3)(CH_2(OH)))=$.

14. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^2 is C_{3-10} cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is optionally substituted with one to four Z^1.


15. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^2 is


, each optionally substituted with one to four Z^1.


16. The compound of any of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein

R^2 is


, each optionally substituted with one to four Z^1.


17. The compound of any of claims 1-14 and 16, or a pharmaceutically acceptable salt thereof, wherein,

R^2 is


.

18. The compound of any of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein

R^2 is



, wherein


R^{2a} is C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{2b} is H, or C_{1-3} alkyl; and

R^{2c} is H, or C_{1-3} alkyl.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein

R^2 is



20. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each Z^1 is independently C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, oxo, -OH, -CN, C_{1-6} alkyl-CN, -C(O)R^{10a}, -C(O)O- R^{10a}, -C(O)NH_2, -C(O)NH(C_{1-9} alkyl), -N(R^{10a})(R^{10b}), -N(R^{10a})C(O)O- R^{10b}, -N(R^{10a})C(O)- R^{10b}, -S(O)$_2$ R^{10a}, or -S(O)$_2$(C_{1-9} alkyl).

21. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, wherein

each Z^1 is independently C_{1-6} alkyl, C_{1-6} alkoxy, halogen, oxo, -C(O)R^{10a}, -C(O)O- R^{10a}, -C(O)NH_2, -C(O)NH(C_{1-9} alkyl), -N(R^{10a})(R^{10b}), -N(R^{10a})C(O)O- R^{10b}, -N(R^{10a})C(O)- R^{10b}, -S(O)$_2$ R^{10a}, or -S(O)$_2$(C_{1-9} alkyl).

22. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each Z^1 is independently C_{1-6} alkyl, C_{1-6} alkoxy, halogen, or C_{1-6} haloalkyl.

23. The compound of any or the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^3 is -C(O)OH.

24. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^4 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, halogen, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, $-NO_2$, -CN, $-N_3$, $-O-R^{10a}$, $-C(O)R^{10a}$, $-C(O)O-R^{10}R^{10a}$, $-N(R^{10a})(R^{10b})$, $-N(R^{10a})_2(R^{10b})^+$, $-N(R^{10a})-C(O)R^{10b}$, $-N(R^{10a})S(O)_2-N(R^{10b})(R^{10c})$, $-S(O)R^{10a}$, or $-S(O)(NR^{10a})R^{10b}$ $-S(O)_2R^{10a}$.

25. The compound of any the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^4 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, halogen, C_{3-10} cycloalkyl, heteroaryl, or $-C(O)R^{10a}$.

26. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^5 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, heteroaryl, C_{6-10} aryl, heteroaryl, oxo, , $-N_3$, -CN, $-O-R^{10a}$, $-C(O)-R^{10a}$, $-C(O)O-R^{10a}$, $C(O)-N(R^{10a})(R^{10b})$, $-N(R^{10a})(R^{10b})$, $-N(R^{10a})_2(R^{10b})^+$, $-N(R^{10a}R^{10b})C(O)-R^{10b}$, $-N(R^{10a})C(O)O-R^{10b}$, $-N(R^{10a})C(O)N(R^{10b})(R^{10c})$, or $-OC(O)-N(R^{10a})(R^{10b})$.

27. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof wherein,

each R^5 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{3-15} cycloalkyl, heteroaryl, or -CN.

28. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^6 is independently C_{1-9} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-8} haloalkyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, $-O(C_{1-9}$ alkyl), $-O(C_{1-8}$ haloalkyl), $-O(C_{2-6}$ alkenyl), $-O(C_{2-6}$ alkynyl), $-O(C_{3-15}$ cycloalkyl), -O(heterocyclyl), $-O(C_{6-10}$ aryl), -

O(heteroaryl), - NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{2-6} alkenyl), -NH(C_{2-6} alkynyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(C_{6-10} aryl), or -NH(heteroaryl).

29. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^6 is independently C_{1-9} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-8} haloalkyl, C_{3-15} cycloalkyl or halogen.


30. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^7 is independently C_{1-9} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-8} haloalkyl, oxo, -OH, -CN, $-NH_2$, or halogen.

31. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

each R^7 is C_{2-6} alkoxyalkyl.

32. A compound of Formula (II)



(II)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is a phenyl or 6 membered heteroaryl optionally substituted with R^4;

X^1 is –C(H)= or –C(R^8)=;

X^4 is -C(R^8)= or N; Each R^4 is independently C_{1-9} alkyl, C_{1-8} haloalkyl, or halogen;


each R^8 is independently halogen; and

n is 0, 1, 2, or 3.







33. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^1 is phenyl, substituted with halogen or -CN.

34. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^1 is , substituted with halogen or -CN.

35. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is

, , , , , , or .

36. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^8 is F or Cl.

37. The compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, having the structure of a compound in Table 2.

38. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any one of claims 1-36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

39. The pharmaceutical composition of claim 38 further comprising one or more additional therapeutic agents.

40. The pharmaceutical composition of claim 38 for use in treating a glucagon-like peptide 1 receptor (GLP-1R) mediated disease or condition.

41. A method of treating GLP-1R mediated disease or condition comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof.

42. The method of claim 41, wherein the disease or condition comprises a liver disease.

43. The method of claim 42, wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Choleangitis (PSC).

44. The method of claim 43, wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

45. The method of claim 43, wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

46. The method of claim 41, wherein the disease or condition comprises a metabolic disease.

47. The method of claim 41, wherein the disease or condition comprises type 1 diabetes, type 2 diabetes, pre-diabetes, idiopathic type 1 diabetes, latent autoimmune diabetes, maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

48. The method of any one of claims 41 to 47, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent.

49. The pharmaceutical composition of claim 39 or the method of claim 48, wherein the additional therapeutic agent comprises an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor (*e.g.*, orlistat), a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R) (*e.g.*, setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (*e.g.*, obeticholic acid), apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor (*e.g.*, buproprion), an opioid receptor antagonist (*e.g.*, naltrexone), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist (*e.g.*, a combination of bupropion and naltrexone), a GDF-15 analog, sibutramine, a cholecystokinin agonist, amylin and analogues thereof (*e.g.*, pramlintide), leptin and analogues thereof (*e.g.*, metroleptin), a serotonergic agent (*e.g.*, lorcaserin), a methionine aminopeptidase 2 (MetAP2) inhibitor (*e.g.*, beloranib or ZGN-1061), phendimetrazine, diethylpropion, benzphetamine, an SGLT2 inhibitor (*e.g.*, empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, or ertugliflozin), an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist, *e.g.*, liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.


50. A method for manufacturing a medicament for treating a GLP-1R mediated disease or condition in a human in need thereof, characterized in that a compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, is used.

51. Use of the compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a GLP-1R mediated disease or condition.

52. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, for use in treating a GLP-1R mediated disease or condition in a human in need thereof.

CLAIMS:

1. A compound of Formula (II)



(II)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is a phenyl or 6 membered heteroaryl optionally substituted with 1, 2, or 3 R^4;

X^1 is –C(H)= or –C(R^8)=;

X^4 is –C(H)=, -C(R^8)= or N;

each R^4 is independently halogen or -CN;

each R^B is independently C_{1-9} alkyl, C_{1-8} haloalkyl, or halogen;


each R^8 is independently H or halogen; and

n is 0, 1, 2, or 3.








2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is phenyl, substituted with halogen or -CN.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein






R^1 is , substituted with halogen or -CN.


4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is











5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^8 is F or Cl.


6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:


































































































































































































































































































































































































































.


7. The compound of claim 1 having the structure:



,

or a pharmaceutically acceptable salt thereof.


8. The compound of claim 1 having the structure:



,

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

11. The pharmaceutical composition of claim 10 further comprising one or more additional therapeutic agents.

12. Use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a glucagon-like peptide 1 receptor (GLP-1R) mediated disease or condition.

13. The use of claim 12, wherein the disease or condition comprises a liver disease.

14. The use of claim 13, wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Choleangitis (PSC).

15. The use of claim 14, wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

16. The use of claim 14, wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

17. The use of claim 12, wherein the disease or condition comprises a metabolic disease.

18. The use of claim 12, wherein the disease or condition comprises type 1 diabetes, type 2 diabetes, pre-diabetes, idiopathic type 1 diabetes, latent autoimmune diabetes,

maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

19. The use of any one of claims 12 to 18, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in combination with an additional therapeutic agent.

20. The pharmaceutical composition of claim 11 or the use of claim 19, wherein the additional therapeutic agent comprises an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor (*e.g.*, orlistat), a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R) (*e.g.*, setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (*e.g.*, obeticholic acid), apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor (*e.g.*, buproprion), an opioid receptor antagonist (*e.g.*, naltrexone), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist (*e.g.*, a combination of bupropion and naltrexone), a GDF-15 analog, sibutramine, a cholecystokinin agonist, amylin and analogues thereof (*e.g.*, pramlintide), leptin and analogues thereof (*e.g.*, metroleptin), a serotonergic agent (*e.g.*, lorcaserin), a methionine aminopeptidase 2 (MetAP2) inhibitor (*e.g.*, beloranib or ZGN-1061), phendimetrazine, diethylpropion,

benzphetamine, an SGLT2 inhibitor (*e.g.*, empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, or ertugliflozin), an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist, *e.g.*, liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.